Hemenway Trust Co LLC Has $32.66 Million Stock Holdings in Johnson & Johnson $JNJ

Hemenway Trust Co LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 9.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 176,157 shares of the company’s stock after selling 17,948 shares during the quarter. Johnson & Johnson comprises 2.5% of Hemenway Trust Co LLC’s portfolio, making the stock its 15th biggest holding. Hemenway Trust Co LLC’s holdings in Johnson & Johnson were worth $32,663,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Cumberland Partners Ltd raised its stake in shares of Johnson & Johnson by 474.7% in the third quarter. Cumberland Partners Ltd now owns 67,815 shares of the company’s stock worth $12,574,000 after acquiring an additional 56,015 shares during the last quarter. King Luther Capital Management Corp increased its holdings in shares of Johnson & Johnson by 46.7% in the third quarter. King Luther Capital Management Corp now owns 655,724 shares of the company’s stock valued at $121,584,000 after purchasing an additional 208,853 shares in the last quarter. Avestar Capital LLC raised its position in Johnson & Johnson by 7.1% in the 3rd quarter. Avestar Capital LLC now owns 17,731 shares of the company’s stock worth $3,288,000 after purchasing an additional 1,181 shares during the last quarter. CFO4Life Group LLC lifted its holdings in Johnson & Johnson by 1.7% during the 3rd quarter. CFO4Life Group LLC now owns 10,855 shares of the company’s stock worth $2,013,000 after buying an additional 179 shares in the last quarter. Finally, Piedmont Capital Management LLC boosted its position in Johnson & Johnson by 2.7% in the 3rd quarter. Piedmont Capital Management LLC now owns 5,585 shares of the company’s stock valued at $1,028,000 after buying an additional 147 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Announced a >$1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania as part of a multi‑year U.S. manufacturing expansion — expands capacity for JNJ’s cell/biologic pipeline and signals long‑term revenue growth potential. Read More.
• Positive Sentiment: FDA approved a simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab + hyaluronidase), improving convenience for EGFR+ NSCLC patients and potentially boosting uptake and product competitiveness. Read More.
• Positive Sentiment: Received FDA Breakthrough Therapy Designation for subcutaneous amivantamab (RYBREVANT FASPRO) in advanced head & neck cancer — could speed development and improve commercial prospects if confirmatory data follow. Read More.
• Positive Sentiment: Raised the quarterly dividend to $1.30 (annualized $5.20), reinforcing the shareholder‑yield profile that supports income‑oriented ownership. Read More.
• Neutral Sentiment: Options activity around JNJ has increased, which can amplify short‑term moves; useful for traders but not a fundamental driver by itself. Read More.
• Neutral Sentiment: Small contract extension with Trellus Health keeps a patient‑support program in place — operationally positive but immaterial to overall revenue. Read More.
• Negative Sentiment: Insider selling: two executive vice presidents disclosed sizable stock sales this week (Vanessa Broadhurst sold ~6,197 shares at ~$243.39; Timothy Schmid sold ~22,623 shares at ~$244.33). Large insider sales can weigh on sentiment even if motivated by diversification or tax planning. Read More.
• Negative Sentiment: Ongoing talc litigation and recent verdict coverage keep legal risk and potential liabilities on the radar — this continues to cap valuation upside despite operational wins. Read More.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on JNJ shares. Morgan Stanley set a $262.00 price target on Johnson & Johnson and gave the company an “overweight” rating in a research note on Wednesday, January 28th. Bank of America upped their target price on shares of Johnson & Johnson from $220.00 to $221.00 and gave the company a “neutral” rating in a research report on Thursday, January 22nd. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. HSBC increased their price objective on shares of Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a report on Friday, January 30th. Finally, Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $233.73.

Johnson & Johnson Stock Up 0.6%

Johnson & Johnson stock opened at $244.89 on Thursday. The firm has a market capitalization of $590.17 billion, a price-to-earnings ratio of 22.16, a PEG ratio of 2.36 and a beta of 0.35. The company’s 50 day simple moving average is $219.71 and its 200 day simple moving average is $198.21. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $246.35.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is currently 47.06%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.